JP6000283B2 - Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン - Google Patents
Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン Download PDFInfo
- Publication number
- JP6000283B2 JP6000283B2 JP2013551360A JP2013551360A JP6000283B2 JP 6000283 B2 JP6000283 B2 JP 6000283B2 JP 2013551360 A JP2013551360 A JP 2013551360A JP 2013551360 A JP2013551360 A JP 2013551360A JP 6000283 B2 JP6000283 B2 JP 6000283B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- methyl
- cyclopenta
- pentamethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)([C@]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@](CC1)[C@]2(C)[C@@]2(C)[C@]1[C@@]([C@@](CC1)C(C)=C)[C@@]1(C*)CC2 Chemical compound CC(C)([C@]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@](CC1)[C@]2(C)[C@@]2(C)[C@]1[C@@]([C@@](CC1)C(C)=C)[C@@]1(C*)CC2 0.000 description 7
- FVTHVBZTYOBMNO-YGSKVSAXSA-N CC(C)(C)OC(c(cc1)ccc1C(C(C)(C)[C@@H]1CC2)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCN(C)C)CC2)=O Chemical compound CC(C)(C)OC(c(cc1)ccc1C(C(C)(C)[C@@H]1CC2)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCN(C)C)CC2)=O FVTHVBZTYOBMNO-YGSKVSAXSA-N 0.000 description 1
- QXRCGZFEZZYUFA-IDGVJNQSSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(NS(C3CC3)(=O)=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCN(CC1)CCS1(=O)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(NS(C3CC3)(=O)=O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCN(CC1)CCS1(=O)=O)CC2 QXRCGZFEZZYUFA-IDGVJNQSSA-N 0.000 description 1
- XOCBSNMQBALXLW-LUEHRWBFSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H](C(CC1)C(C)=C)[C@@]1(CNCc(cc1)ccc1S(N)(=O)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H](C(CC1)C(C)=C)[C@@]1(CNCc(cc1)ccc1S(N)(=O)=O)CC2 XOCBSNMQBALXLW-LUEHRWBFSA-N 0.000 description 1
- JDRKZGANIVKGKR-CEQCIRHOSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNC(C1NCCC1)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNC(C1NCCC1)=O)CC2 JDRKZGANIVKGKR-CEQCIRHOSA-N 0.000 description 1
- KTVSULGDCKKLMJ-YHTJVIJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNC(NCC(O)=O)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNC(NCC(O)=O)=O)CC2 KTVSULGDCKKLMJ-YHTJVIJHSA-N 0.000 description 1
- JWQJWZUBKXPNBM-ASOKESLTSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNC(c(cc1)ccc1S(N)(=O)=O)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNC(c(cc1)ccc1S(N)(=O)=O)=O)CC2 JWQJWZUBKXPNBM-ASOKESLTSA-N 0.000 description 1
- BJEFETLGPUCOGY-QEQIKUMISA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNC1(CC1)C(OC)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNC1(CC1)C(OC)=O)CC2 BJEFETLGPUCOGY-QEQIKUMISA-N 0.000 description 1
- SWIUMSIQYJGYIG-PQYYYUBBSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCC(N1CCCC1)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCC(N1CCCC1)=O)CC2 SWIUMSIQYJGYIG-PQYYYUBBSA-N 0.000 description 1
- LLSFSZHADOTSMU-JRVWIGLXSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCC(O)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCC(O)=O)CC2 LLSFSZHADOTSMU-JRVWIGLXSA-N 0.000 description 1
- RMCWUKRKYKEYGD-QWQYNPTISA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCC(N(CCC1)[C@@H]1C(OC)=O)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCC(N(CCC1)[C@@H]1C(OC)=O)=O)CC2 RMCWUKRKYKEYGD-QWQYNPTISA-N 0.000 description 1
- WWXJHMSSGQTRGY-VREVVNBHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCC(N1CCCC1)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCC(N1CCCC1)=O)CC2 WWXJHMSSGQTRGY-VREVVNBHSA-N 0.000 description 1
- FEGKZTVSOPPFSN-BHVYCOFMSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCC(NC)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCC(NC)=O)CC2 FEGKZTVSOPPFSN-BHVYCOFMSA-N 0.000 description 1
- GEYVJYDLGYOPRC-YQUHGRJISA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCBr)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCBr)CC2 GEYVJYDLGYOPRC-YQUHGRJISA-N 0.000 description 1
- JWVCYYQJYPRCRP-JGHBEAQXSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCN(C(CCC1)=O)C1=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCN(C(CCC1)=O)C1=O)CC2 JWVCYYQJYPRCRP-JGHBEAQXSA-N 0.000 description 1
- VFVHFJQRBLCELT-GXYXSIBPSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCN(C)C)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCCN(C)C)CC2 VFVHFJQRBLCELT-GXYXSIBPSA-N 0.000 description 1
- WBZCLKKAWZJRNV-YQUHGRJISA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCS(C)(=O)=O)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCCS(C)(=O)=O)CC2 WBZCLKKAWZJRNV-YQUHGRJISA-N 0.000 description 1
- CNHYQGJAVGDHDM-GXYXSIBPSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCC[n]1cncc1)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(CNCC[n]1cncc1)CC2 CNHYQGJAVGDHDM-GXYXSIBPSA-N 0.000 description 1
- SNLYAKPAMYNIEN-IDGVJNQSSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(COCCCN(CC1)CCS1=C(C)OC)CC2 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@@]2(C)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]1(COCCCN(CC1)CCS1=C(C)OC)CC2 SNLYAKPAMYNIEN-IDGVJNQSSA-N 0.000 description 1
- XVUGIRZZANVASX-YLNVBRMASA-N CC(CNC[C@@](CC[C@H]1C(C)=C)(CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@]1(C)[C@@H]2C(C)(C)C(c(cc2)ccc2C(O)=O)=CC1)CN(CCC1)C1=O Chemical compound CC(CNC[C@@](CC[C@H]1C(C)=C)(CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@]1(C)[C@@H]2C(C)(C)C(c(cc2)ccc2C(O)=O)=CC1)CN(CCC1)C1=O XVUGIRZZANVASX-YLNVBRMASA-N 0.000 description 1
- OFKULFWRBUXWKQ-PQYYYUBBSA-N CCC([C@H](CC1)[C@H]([C@H]2CC3)[C@@]1(CNCCC(N(C)C)=O)CC[C@@]2(C)[C@](C)(CC1)[C@H]3[C@]2(C)[C@@H]1C(C)(C)C(c(cc1)ccc1C(O)=O)=CC2)=C Chemical compound CCC([C@H](CC1)[C@H]([C@H]2CC3)[C@@]1(CNCCC(N(C)C)=O)CC[C@@]2(C)[C@](C)(CC1)[C@H]3[C@]2(C)[C@@H]1C(C)(C)C(c(cc1)ccc1C(O)=O)=CC2)=C OFKULFWRBUXWKQ-PQYYYUBBSA-N 0.000 description 1
- OLQUNWGZDAWVKP-WCENMHOUSA-N CCN(CC)CCNC[C@@](CC[C@H]1C(C)=C)(CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@]1(C)[C@@H]2C(C)(C)C(c(cc2)ccc2C(O)=O)=CC1 Chemical compound CCN(CC)CCNC[C@@](CC[C@H]1C(C)=C)(CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@]1(C)[C@@H]2C(C)(C)C(c(cc2)ccc2C(O)=O)=CC1 OLQUNWGZDAWVKP-WCENMHOUSA-N 0.000 description 1
- VUYOLIKWIVQHBC-UHFFFAOYSA-N CN(C(CCC1)=O)C1=O Chemical compound CN(C(CCC1)=O)C1=O VUYOLIKWIVQHBC-UHFFFAOYSA-N 0.000 description 1
- LFHMKODCPPOLIB-UHFFFAOYSA-N CN(CC1)CCC1(F)F Chemical compound CN(CC1)CCC1(F)F LFHMKODCPPOLIB-UHFFFAOYSA-N 0.000 description 1
- AXGLXFHGUWLXGU-UHFFFAOYSA-N CN(CC1)CCS1(=O)=[O]CN(CC1)CC1(F)F Chemical compound CN(CC1)CCS1(=O)=[O]CN(CC1)CC1(F)F AXGLXFHGUWLXGU-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N CN(CCC1)C1=O Chemical compound CN(CCC1)C1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- GGYVTHJIUNGKFZ-UHFFFAOYSA-N CN(CCCC1)C1=O Chemical compound CN(CCCC1)C1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N CN1CCCC1 Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- KDTVWEHAAISPNW-UHFFFAOYSA-N CN1CCSCC1 Chemical compound CN1CCSCC1 KDTVWEHAAISPNW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437870P | 2011-01-31 | 2011-01-31 | |
| US61/437,870 | 2011-01-31 | ||
| PCT/US2012/022847 WO2012106188A1 (en) | 2011-01-31 | 2012-01-27 | C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507422A JP2014507422A (ja) | 2014-03-27 |
| JP2014507422A5 JP2014507422A5 (cg-RX-API-DMAC7.html) | 2015-02-26 |
| JP6000283B2 true JP6000283B2 (ja) | 2016-09-28 |
Family
ID=45567146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551360A Expired - Fee Related JP6000283B2 (ja) | 2011-01-31 | 2012-01-27 | Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン |
Country Status (19)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754069B2 (en) | 2011-09-21 | 2014-06-17 | Bristol-Myers Squibb Company | Betulinic acid derivatives with antiviral activity |
| US8906889B2 (en) | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) * | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| RU2516952C1 (ru) * | 2012-11-09 | 2014-05-20 | Леонид Леонидович Клопотенко | Фармацевтическая композиция, содержащая инкапсулированную тритерпеновую кислоту или ее производные |
| RU2519133C1 (ru) * | 2012-11-09 | 2014-06-10 | Леонид Леонидович Клопотенко | Мазь, содержащая инкапсулированную тритерпеновую кислоту или ее производные |
| CN103214543B (zh) * | 2012-12-25 | 2015-09-02 | 中国人民解放军海军医学研究所 | 新山楂酸衍生物、其制备方法及其在抗肿瘤药物中的应用 |
| JP6186010B2 (ja) * | 2013-02-06 | 2017-08-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類 |
| EA027861B1 (ru) * | 2013-02-25 | 2017-09-29 | Бристол-Майерс Сквибб Компани | C-3 алкил- и алкенилмодифицированные производные бетулиновой кислоты или их фармацевтические соли, противовирусная фармацевтическая композиция и фармацевтическая композиция для лечения вич на их основе |
| SMT202000581T1 (it) | 2014-04-11 | 2020-11-10 | Viiv Healthcare Uk No 4 Ltd | Triterpenoidi con attività di inibizione della maturazione di hiv, sostituiti in posizione 3 con un anello non aromatico portante un sostituente alogenoalchilico |
| US9920090B2 (en) * | 2014-06-19 | 2018-03-20 | VIIV Healthcare UK (No.5) Limited | Betulinic acid derivatives with HIV maturation inhibitory activity |
| US9969767B2 (en) | 2014-11-14 | 2018-05-15 | VIIV Healthcare UK (No.5) Limited | Oxolupene derivatives |
| BR112017009853A2 (pt) * | 2014-11-14 | 2018-01-16 | Viiv Healthcare Uk No 5 Ltd | composto, composição, uso de uma quantidade melhoradora de hiv de um composto |
| WO2016077569A1 (en) | 2014-11-14 | 2016-05-19 | Bristol-Myers Squibb Company | C17-aryl substituted betulinic acid analogs |
| US20180094019A1 (en) * | 2015-04-14 | 2018-04-05 | ViiV Healthcare UK (No.4) Limited | Crystalline forms of modified triterpenoid hydrochloride salts with hiv maturation inhibitor activity |
| CA2993758A1 (en) * | 2015-07-28 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Betuin derivatives for preventing or treating hiv infections |
| EP3328876A1 (en) | 2015-07-28 | 2018-06-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Betuin derivatives for preventing or treating hiv infections |
| JP2018528231A (ja) | 2015-09-24 | 2018-09-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｈｉｖ成熟阻害活性を有する化合物 |
| CA3011616A1 (en) | 2016-01-20 | 2017-07-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Amine derivatives of lupanes with hiv maturation inhibitory activity |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP3478703A1 (en) * | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| WO2019055280A1 (en) * | 2017-09-13 | 2019-03-21 | Emmyon, Inc. | DIETHANOLAMINE SALTS AND URSOLIC ACID MORPHOLIN |
| RU2758376C2 (ru) | 2017-09-14 | 2021-10-28 | Феникс Байотекнолоджи, Инк. | Способ и улучшенная нейропротекторная композиция для лечения неврологических патологических состояний |
| AU2018334386B2 (en) | 2017-09-14 | 2021-11-04 | Phoenix Biotechnology, Inc. | Method and composition for treating viral infection |
| ES2970042T3 (es) | 2018-04-24 | 2024-05-24 | Viiv Healthcare Uk No 5 Ltd | Compuestos con actividad inhibidora de la maduración del VIH |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
| US10343997B1 (en) | 2018-12-04 | 2019-07-09 | King Saud University | Ursolic acid derivatives |
| SG11202105728YA (en) | 2020-03-31 | 2021-11-29 | Phoenix Biotechnology Inc | Method and compositions for treating coronavirus infection |
| EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
| US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| AU2005224260A1 (en) | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
| CN101142227A (zh) * | 2004-11-12 | 2008-03-12 | 帕纳克斯医药公司 | 新颖的桦木醇衍生物、其制备和其用途 |
| TW200628161A (en) * | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| CA2714049A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17.beta. lupane derivatives |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| RS54239B1 (sr) * | 2010-06-04 | 2015-12-31 | Bristol-Myers Squibb Company | C-28 amidi modifikovanih derivata c-3 betulinske kiseline kao inhibitori sazrevanja hiv-a |
| CA2801487C (en) * | 2010-06-04 | 2017-12-05 | Bristol-Myers Squibb Company | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| KR101886467B1 (ko) * | 2011-01-31 | 2018-08-07 | 비브 헬스케어 유케이 (넘버4) 리미티드 | Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드 |
-
2012
- 2012-01-27 CN CN201280007020.0A patent/CN103339141B/zh not_active Expired - Fee Related
- 2012-01-27 PT PT127029460T patent/PT2670764E/pt unknown
- 2012-01-27 PL PL12702946T patent/PL2670764T3/pl unknown
- 2012-01-27 BR BR112014010105A patent/BR112014010105A2/pt unknown
- 2012-01-27 JP JP2013551360A patent/JP6000283B2/ja not_active Expired - Fee Related
- 2012-01-27 SI SI201230354T patent/SI2670764T1/sl unknown
- 2012-01-27 EA EA201391098A patent/EA023578B1/ru not_active IP Right Cessation
- 2012-01-27 US US13/359,680 patent/US8748415B2/en not_active Expired - Fee Related
- 2012-01-27 MX MX2013008359A patent/MX2013008359A/es active IP Right Grant
- 2012-01-27 RS RS20150740A patent/RS54352B1/sr unknown
- 2012-01-27 HU HUE12702946A patent/HUE026371T2/en unknown
- 2012-01-27 EP EP12702946.0A patent/EP2670764B1/en active Active
- 2012-01-27 ES ES12702946.0T patent/ES2552512T3/es active Active
- 2012-01-27 CA CA2826257A patent/CA2826257A1/en not_active Abandoned
- 2012-01-27 WO PCT/US2012/022847 patent/WO2012106188A1/en not_active Ceased
- 2012-01-27 DK DK12702946.0T patent/DK2670764T3/en active
- 2012-01-27 HR HRP20151212TT patent/HRP20151212T1/hr unknown
-
2015
- 2015-12-01 SM SM201500303T patent/SMT201500303B/it unknown
- 2015-12-01 CY CY20151101099T patent/CY1116989T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE026371T2 (en) | 2016-05-30 |
| WO2012106188A1 (en) | 2012-08-09 |
| EP2670764B1 (en) | 2015-09-02 |
| DK2670764T3 (en) | 2015-12-07 |
| CN103339141B (zh) | 2016-08-24 |
| PT2670764E (pt) | 2015-11-20 |
| EA201391098A1 (ru) | 2013-12-30 |
| SMT201500303B (it) | 2016-01-08 |
| EP2670764A1 (en) | 2013-12-11 |
| ES2552512T3 (es) | 2015-11-30 |
| MX2013008359A (es) | 2013-08-27 |
| EA023578B1 (ru) | 2016-06-30 |
| US8748415B2 (en) | 2014-06-10 |
| CY1116989T1 (el) | 2017-04-05 |
| CN103339141A (zh) | 2013-10-02 |
| PL2670764T3 (pl) | 2016-02-29 |
| US20130029954A1 (en) | 2013-01-31 |
| RS54352B1 (sr) | 2016-02-29 |
| CA2826257A1 (en) | 2012-08-09 |
| HRP20151212T1 (hr) | 2015-12-04 |
| JP2014507422A (ja) | 2014-03-27 |
| SI2670764T1 (sl) | 2016-03-31 |
| BR112014010105A2 (pt) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6000283B2 (ja) | Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン | |
| JP5755731B2 (ja) | Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体のｃ−２８アミド | |
| JP6212545B2 (ja) | Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド | |
| JP6155285B2 (ja) | Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド | |
| JP6186012B2 (ja) | Ｃ−３アルキルおよびアルケニル修飾ベツリン酸誘導体 | |
| KR102411082B1 (ko) | 할로알킬 치환기를 지니는 비방향족 고리에 의해 위치 3에서 치환된，ｈｉｖ 성숙화 억제 활성을 갖는 트리테르페노이드 | |
| JP6100786B2 (ja) | 抗ウイルス活性を有する新規ベツリン酸誘導体 | |
| CN103429607A (zh) | 具有hiv成熟抑制活性的c-17和c-3经修饰的三萜系化合物 | |
| HK40041853A (en) | Triterpenoids with hiv maturation inhibitory activity | |
| HK1232548B (en) | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent | |
| NZ614871B2 (en) | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160105 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160325 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160830 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6000283 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |